Literature DB >> 22133326

Atypical antipsychotic-induced weight gain: insights into mechanisms of action.

James L Roerig1, Kristine J Steffen, James E Mitchell.   

Abstract

Prescriptions for second-generation antipsychotics (SGAs) have surpassed those for first-generation agents in the treatment of schizophrenia and bipolar disorder. While SGAs have the benefit of a much reduced risk of causing movement disorders, they have been associated with weight gain and metabolic effects. These adverse reactions are not uncommon, and threaten to have a significant impact on the patient's health over the long-term treatment that the patient requires. Currently, the aetiology of these effects is not known. This article reviews the data exploring the weight gain phenomenon. The literature was reviewed from searches of PubMed and the references of major articles in the field. The SGAs present a heterogeneous risk for weight gain. In addition, different individuals receiving the same drug can exhibit substantially different weight changes. This pattern suggests that a group of factors are associated with the weight gain phenomenon rather than a single mechanism. Coupled with the genetic profile that the patient brings to the treatment, the risk for SGA-induced weight gain will be different for different drugs and different individuals. Targets for exploration of the weight gain phenomenon include receptor interactions involving serotonin, histamine, dopamine, adrenergic, cannabinoid and muscarinic receptors. The association of SGA-induced weight gain and the role of orexigenic and anorexigenic peptides are reviewed. Also, a brief discussion of genetic factors associated with SGA-induced weight gain is presented, including that of the serotonin 5-HT(2C) receptor gene (HTR2C) and the cannabinoid 1 receptor gene (CNR1). The most promising data associated with SGA-induced weight gain include investigations of the histamine H(1), 5-HT(2A), 5-HT(2C), muscarinic M(3) and adrenergic receptors. In addition, work in the genetic area promises to result in a better understanding of the variation in risk associated with different individuals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133326     DOI: 10.2165/11596300-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  224 in total

1.  Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Authors:  B R Basson; B J Kinon; C C Taylor; K A Szymanski; J A Gilmore; G D Tollefson
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

2.  -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain.

Authors:  Shih-Jen Tsai; Chen-Jee Hong; Younger W-Y Yu; Ching-Hua Lin
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

3.  A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo.

Authors:  Dinesh Gautam; Sung-Jun Han; Fadi F Hamdan; Jongrye Jeon; Bo Li; Jian Hua Li; Yinghong Cui; David Mears; Huiyan Lu; Chuxia Deng; Thomas Heard; Jürgen Wess
Journal:  Cell Metab       Date:  2006-06       Impact factor: 27.287

4.  -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.

Authors:  Seunghyong Ryu; Eun Young Cho; Taesung Park; Sohee Oh; Won-Seok Jang; Shin-Kyum Kim; Dongsoo Lee; Kyung Sue Hong
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-01-12       Impact factor: 5.067

5.  Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.

Authors:  Rocio Peña; David Marquina; Ana Serrano; Yamily Elfakih; Enma Araujo de Baptista; Edgardo Carrizo; Virginia Fernández; Lenin Valery; Luis Teneud; Trino Baptista
Journal:  Schizophr Res       Date:  2008-10-02       Impact factor: 4.939

6.  Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.

Authors:  J S Silvestre; J Prous
Journal:  Methods Find Exp Clin Pharmacol       Date:  2005-06

7.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.

Authors:  D E Cummings; J Q Purnell; R S Frayo; K Schmidova; B E Wisse; D S Weigle
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

8.  A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.

Authors:  Seung-Yup Lee; Min-Hyeon Park; Ashwin A Patkar; Chi-Un Pae
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-12-10       Impact factor: 5.067

Review 9.  Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.

Authors:  Stephen C Woods
Journal:  Am J Med       Date:  2007-03       Impact factor: 4.965

10.  Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus.

Authors:  T Baptista; L Hernandez; B G Hoebel
Journal:  Pharmacol Biochem Behav       Date:  1990-10       Impact factor: 3.533

View more
  40 in total

1.  The prevalence and independent influencing factors of obesity and underweight in patients with schizophrenia: a multicentre cross-sectional study.

Authors:  Juan Wang; Yulong Zhang; Yating Yang; Zhiwei Liu; Lei Xia; Wenzheng Li; Zhongxiang Li; Xinhui Xie; Wenfeng Deng; Kai Zhang; Huanzhong Liu
Journal:  Eat Weight Disord       Date:  2020-06-17       Impact factor: 4.652

2.  Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Authors:  David E Kemp; Christoph U Correll; Mauricio Tohen; Melissa P Delbello; Stephen J Ganocy; Robert L Findling; Kiki Chang
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-10-10       Impact factor: 2.576

Review 3.  Treatment of clozapine-associated weight gain: a systematic review.

Authors:  Z Whitney; R M Procyshyn; D H Fredrikson; A M Barr
Journal:  Eur J Clin Pharmacol       Date:  2015-01-28       Impact factor: 2.953

Review 4.  Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments.

Authors:  Jeffrey Goltz; Iliyan Ivanov; Timothy R Rice
Journal:  Int J Dev Disabil       Date:  2019-07-14

Review 5.  Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lei Xia; Wen-Zheng Li; Huan-Zhong Liu; Rui Hao; Xiang-Yang Zhang
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-01-22       Impact factor: 2.576

6.  Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.

Authors:  Rajeev Sakhuja; Krishnakanth Kondabolu; Tania Córdova-Sintjago; Sean Travers; Adam S Vincek; Myong Sang Kim; Khalil A Abboud; Lijuan Fang; Zhuming Sun; Clinton E Canal; Raymond G Booth
Journal:  Bioorg Med Chem       Date:  2015-02-07       Impact factor: 3.641

7.  Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.

Authors:  Julia Staeker; Stefan Leucht; Werner Steimer
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.074

8.  Deintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes.

Authors:  Joshua D Niznik; Jacob N Hunnicutt; Xinhua Zhao; Maria K Mor; Florentina Sileanu; Sherrie L Aspinall; Sydney P Springer; Mary J Ersek; Walid F Gellad; Loren J Schleiden; Joseph T Hanlon; Joshua M Thorpe; Carolyn T Thorpe
Journal:  J Am Geriatr Soc       Date:  2020-02-17       Impact factor: 5.562

Review 9.  Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?

Authors:  Kyle J Burghardt; Vicki L Ellingrod
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

10.  Obesity in Women: Insights for the Clinician.

Authors:  Zujaja Tauqeer; Gricelda Gomez; Fatima Cody Stanford
Journal:  J Womens Health (Larchmt)       Date:  2017-10-27       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.